These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25881619)

  • 21. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
    Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
    Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
    Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
    Lieberman-Blum SS; Fung HB; Bandres JC
    Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors associated with optimized tacrolimus dosing in hematopoietic stem cell transplantation.
    Butts AR; Brown VT; McBride LD; Bolaños-Meade J; Bryk AW
    J Oncol Pharm Pract; 2016 Apr; 22(2):275-83. PubMed ID: 25802301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating risk factors for acute graft versus host disease in pediatric hematopoietic stem cell transplant patients receiving tacrolimus.
    Phan M; Chavan R; Beuttler R; Benipayo N; Magedman G; Buchbinder D; Tomaszewski D; Yang S
    Clin Transl Sci; 2021 Jul; 14(4):1303-1313. PubMed ID: 33503293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
    Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaques.
    Winters MA; Van Rompay KK; Kashuba AD; Shulman NS; Holodniy M
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4059-63. PubMed ID: 20696881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation.
    Aisa Y; Mori T; Nakazato T; Shimizu T; Yamazaki R; Ikeda Y; Okamoto S
    Transplantation; 2005 Oct; 80(8):1046-50. PubMed ID: 16278584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
    Abel S; Jenkins TM; Whitlock LA; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):38-46. PubMed ID: 18333864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg.
    Okoli C; Siccardi M; Thomas-William S; Dufty N; Khonyongwa K; Ainsworth J; Watson J; Cook R; Gandhi K; Hickinbottom G; Owen A; Taylor S
    J Antimicrob Chemother; 2012 Mar; 67(3):671-4. PubMed ID: 22174038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation.
    Mori T; Kato J; Yamane A; Sakurai M; Kohashi S; Kikuchi T; Ono Y; Okamoto S
    Int J Hematol; 2012 May; 95(5):564-9. PubMed ID: 22461034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
    Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
    Rosario MC; Jacqmin P; Dorr P; James I; Jenkins TM; Abel S; van der Ryst E
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):86-94. PubMed ID: 18333870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Khaled SK; Palmer JM; Herzog J; Stiller T; Tsai NC; Senitzer D; Liu X; Thomas SH; Shayani S; Weitzel J; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):268-276. PubMed ID: 26325438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.
    Rosario MC; Poland B; Sullivan J; Westby M; van der Ryst E
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):183-91. PubMed ID: 16639345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycophenolate mofetil administered every 8 hours in combination with tacrolimus is efficacious in the prophylaxis of acute graft versus host disease in childhood, adolescent, and young adult allogeneic stem cell transplantation recipients.
    Militano O; Ozkaynak MF; Mehta B; van deVen C; Hamby C; Cairo MS
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27091. PubMed ID: 29667720
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of CYP3A5 polymorphism on the pharmacokinetics of a once-daily modified-release tacrolimus formulation and acute kidney injury in hematopoietic stem cell transplantation.
    Yamashita T; Fujishima N; Miura M; Niioka T; Abumiya M; Shinohara Y; Ubukawa K; Nara M; Fujishima M; Kameoka Y; Tagawa H; Hirokawa M; Takahashi N
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):111-8. PubMed ID: 27217047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women.
    Dumond JB; Patterson KB; Pecha AL; Werner RE; Andrews E; Damle B; Tressler R; Worsley J; Kashuba AD
    J Acquir Immune Defic Syndr; 2009 Aug; 51(5):546-53. PubMed ID: 19546811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tacrolimus dose modification in patients receiving concomitant isavuconazole after hematopoietic stem cell transplantation.
    Trifilio S; Rubin H; Monacelli A; Mehta J
    J Oncol Pharm Pract; 2021 Jun; 27(4):857-862. PubMed ID: 32659173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.